Patent ID: 8734815

Claim:
A recombinant vaccine against leishmaniasis comprising a recombinant A2 protein of amastigote forms of Leishmania that allows serologic distinction between vaccinated and infected animals by conventional serologic tests, ELISA and immunofluorescence using antigens of promastigote forms selected from the group consisting of Leishmania amazonensis, L. donovani, L. infantum, and L. chagasi; wherein the recombinant vaccine contains: (i) recombinant A2-HIS (rA2) protein from 50 μg/mL to 200 μg/mL and saponin from 0.125 mg/mL to 0.500 mg/mL in a buffered saline solution and (ii) 0.01 mL of thimerosal per 1.00 mL of the buffered saline solution.